Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 19458354)

1.

Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming.

Highfill SL, Kelly RM, O'Shaughnessy MJ, Zhou Q, Xia L, Panoskaltsis-Mortari A, Taylor PA, Tolar J, Blazar BR.

Blood. 2009 Jul 16;114(3):693-701. doi: 10.1182/blood-2009-03-213850. Epub 2009 May 20.

2.

Clinical-grade multipotent adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and autoimmunity.

Reading JL, Yang JH, Sabbah S, Skowera A, Knight RR, Pinxteren J, Vaes B, Allsopp T, Ting AE, Busch S, Raber A, Deans R, Tree TI.

J Immunol. 2013 May 1;190(9):4542-52. doi: 10.4049/jimmunol.1202710. Epub 2013 Apr 1.

3.

Human multipotent adult progenitor cells are nonimmunogenic and exert potent immunomodulatory effects on alloreactive T-cell responses.

Jacobs SA, Pinxteren J, Roobrouck VD, Luyckx A, van't Hof W, Deans R, Verfaillie CM, Waer M, Billiau AD, Van Gool SW.

Cell Transplant. 2013;22(10):1915-28. doi: 10.3727/096368912X657369. Epub 2012 Oct 1.

PMID:
23031260
4.

Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells.

Tolar J, O'shaughnessy MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell S, Riddle M, McIvor RS, Yant SR, Kay MA, Krause D, Verfaillie CM, Blazar BR.

Blood. 2006 May 15;107(10):4182-8. Epub 2006 Jan 12.

5.

Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.

Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR.

Blood. 2010 Dec 16;116(25):5738-47. doi: 10.1182/blood-2010-06-287839. Epub 2010 Aug 31.

8.

Oct4-negative multipotent adult progenitor cells and mesenchymal stem cells as regulators of T-cell alloreactivity in mice.

Luyckx A, De Somer L, Jacobs S, Rutgeerts O, Lenaerts C, Roobrouck VD, Verfaillie CM, Waer M, Van Gool SW, Billiau AD.

Immunol Lett. 2011 Jun 30;137(1-2):78-81. doi: 10.1016/j.imlet.2011.02.021. Epub 2011 Mar 4.

PMID:
21382417
10.

APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease.

Zhang Y, Shlomchik WD, Joe G, Louboutin JP, Zhu J, Rivera A, Giannola D, Emerson SG.

J Immunol. 2002 Dec 15;169(12):7111-8.

11.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.

PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6.

12.

Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease.

Kovacsovics-Bankowski M, Streeter PR, Mauch KA, Frey MR, Raber A, van't Hof W, Deans R, Maziarz RT.

Cell Immunol. 2009;255(1-2):55-60. doi: 10.1016/j.cellimm.2008.10.004. Epub 2008 Nov 20.

PMID:
19022422
13.

A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease.

Tawara I, Shlomchik WD, Jones A, Zou W, Nieves E, Liu C, Toubai T, Duran-Struuck R, Sun Y, Clouthier SG, Evers R, Lowler KP, Levy RB, Reddy P.

J Immunol. 2010 Oct 1;185(7):3866-72. doi: 10.4049/jimmunol.1001625. Epub 2010 Sep 1.

14.

Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.

Giver CR, Montes RO, Mittelstaedt S, Li JM, Jaye DL, Lonial S, Boyer MW, Waller EK.

Biol Blood Marrow Transplant. 2003 Oct;9(10):616-32.

16.

Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice.

Semple K, Yu Y, Wang D, Anasetti C, Yu XZ.

Biol Blood Marrow Transplant. 2011 Mar;17(3):309-18. doi: 10.1016/j.bbmt.2010.12.710. Epub 2011 Jan 9.

17.
18.

Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity.

Zhang Y, Joe G, Zhu J, Carroll R, Levine B, Hexner E, June C, Emerson SG.

Blood. 2004 May 15;103(10):3970-8. Epub 2004 Feb 5.

19.

Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice.

Sudres M, Norol F, Trenado A, Grégoire S, Charlotte F, Levacher B, Lataillade JJ, Bourin P, Holy X, Vernant JP, Klatzmann D, Cohen JL.

J Immunol. 2006 Jun 15;176(12):7761-7.

20.

Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease.

Koyama M, Kuns RD, Olver SD, Raffelt NC, Wilson YA, Don AL, Lineburg KE, Cheong M, Robb RJ, Markey KA, Varelias A, Malissen B, Hämmerling GJ, Clouston AD, Engwerda CR, Bhat P, MacDonald KP, Hill GR.

Nat Med. 2011 Nov 29;18(1):135-42. doi: 10.1038/nm.2597.

PMID:
22127134
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk